====== Translational neuro-oncology research ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/14ipX3fGPZTFtIuJ1-iTHykSnkGRykw2gGJIKKk6uf-cYVyEFC/?limit=15&utm_campaign=pubmed-2&fc=20250226153043}}

**[[Translational]] [[Neuro-Oncology]] [[Research]]** refers to the process of applying discoveries from basic [[neuroscience]] and [[oncology]] research to clinical applications for brain and spinal cord tumors. It bridges the gap between [[laboratory]] findings and [[patient care]] by developing new diagnostic [[tool]]s, treatment strategies, and personalized therapies.

===== Key Areas =====

==== Molecular and Genetic Profiling ====

Identifying [[genetic mutation]]s and [[molecular pathway]]s involved in gliomas, medulloblastomas, and other CNS tumors.  

[[Next-generation sequencing]] (NGS) and [[liquid biopsy]] are used for tumor characterization.  

==== Targeted Therapies and Immunotherapy ====
  
Development of small-molecule inhibitors targeting pathways like EGFR, IDH1, and BRAF mutations.  

Advances in CAR-T cell therapy and checkpoint inhibitors for glioblastoma and other aggressive brain tumors.  

==== Tumor Microenvironment and Drug Resistance  ====
 
Understanding the blood-brain barrier (BBB) and strategies to enhance drug delivery (e.g., focused ultrasound, nanoparticles).  

Studying the role of hypoxia, immune suppression, and glioma stem cells in tumor progression.  

==== Advanced Imaging and Biomarkers  ====
 
Integration of MRI spectroscopy, PET imaging, and AI-driven radiomics for tumor detection and monitoring.  

Identification of biomarkers for early diagnosis and treatment response.  

==== Preclinical Models and Clinical Trials  ====
 
Use of patient-derived xenografts (PDX) and organoids to test new drugs.  

Adaptive trial designs for rapid assessment of novel therapies.  
----

----